This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Carol K. Kasper, MD

JAMA. 1985;254(16):2259-2262.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Appropriate management of patients with hematologic and oncological disorders continues to be controversial. Two topics to be discussed in this year's CONTEMPO are the efficacy of platelet transfusions for patients rendered thrombocytopenic by chemotherapy and the appropriateness of chemotherapy for myelodysplastic anemia. Although no new advances have occurred in the diagnosis of iron deficiency anemia, this problem takes on particular significance in evaluating volunteer blood donors.

Intensive chemotherapy for malignancies has resulted in dramatic increases in platelet transfusions,¹ and these are credited with reducing deaths from hemorrhage in thrombocytopenic patients. Critical questions have been raised, however, about the choice of platelet product to administer. Among patients treated with platelets from random donors harvested from individual whole-blood donations, approximately one third of those who survive the chemotherapy induction phase become alloimmunized.

To delay the emergence of alloimmunization, some clinicians have advocated use of a more restricted number of HLA-unmatched donors . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?